Vera Therapeutics, Inc. - Class A Common Stock, par value $0.001 per share (VERA)
CUSIP: 92337R101
Q1 2025 13F Holders as of 31 Mar 2025
- Type / Class
- Equity / Class A Common Stock, par value $0.001 per share
- Shares outstanding
- 72,325,000
- Total 13F shares
- 62,915,975
- Share change
- -61,349
- Total reported value
- $1,512,522,250
- Put/Call ratio
- 27%
- Price per share
- $24.02
- Number of holders
- 176
- Value change
- -$90,036,678
- Number of buys
- 101
- Number of sells
- 79
Quarterly Holders Quick Answers
What is CUSIP 92337R101?
CUSIP 92337R101 identifies VERA - Vera Therapeutics, Inc. - Class A Common Stock, par value $0.001 per share in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Next holder-history checks
These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.
- Back to full security ownership history for the broader multi-quarter picture.
- Latest 13F filings for newly reported positions across managers.
- Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
- SEC investors directory for manager drilldown.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
Recent filing periods for CUSIP 92337R101:
Top shareholders of VERA - Vera Therapeutics, Inc. - Class A Common Stock, par value $0.001 per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| Avoro Capital Advisors LLC |
13F
13D/G
|
Company |
8.9%
from 13D/G
|
5,610,000
|
$237,246,900 | — | 31 Dec 2024 | |
| PRICE T ROWE ASSOCIATES INC /MD/ |
13F
|
Company |
6.1%
|
4,377,049
|
$185,107,000 | — | 31 Dec 2024 | |
| BlackRock, Inc. |
13F
|
Company |
5.4%
|
3,941,486
|
$166,685,443 | — | 31 Dec 2024 | |
| FMR LLC |
13F
|
Company |
4.2%
|
3,053,126
|
$129,116,698 | — | 31 Dec 2024 | |
| VANGUARD GROUP INC |
13F
|
Company |
4.1%
|
2,949,564
|
$124,737,062 | — | 31 Dec 2024 | |
| Sofinnova Investments, Inc. |
13F
|
Company |
3.9%
|
2,793,987
|
$118,157,710 | — | 31 Dec 2024 | |
| STATE STREET CORP |
13F
|
Company |
2.8%
|
2,026,352
|
$85,694,426 | — | 31 Dec 2024 | |
| Commodore Capital LP |
13F
3/4/5
|
Company · 10%+ Owner |
2.7%
|
1,958,600
|
$82,829,194 | — | 31 Dec 2024 | |
| Holocene Advisors, LP |
13F
|
Company |
2.6%
|
1,875,963
|
$79,334,475 | — | 31 Dec 2024 | |
| SAMLYN CAPITAL, LLC |
13F
|
Company |
2.3%
|
1,662,220
|
$70,295,283 | — | 31 Dec 2024 | |
| Eversept Partners, LP |
13F
|
Company |
2.2%
|
1,600,015
|
$67,664,634 | — | 31 Dec 2024 | |
| Sofinnova Venture Partners X, L.P. |
3/4/5
|
10%+ Owner |
—
class O/S missing
|
3,467,156
|
$62,408,808 | — | 06 Feb 2023 | |
| Kynam Capital Management, LP |
13F
|
Company |
2%
|
1,457,910
|
$61,655,014 | — | 31 Dec 2024 | |
| Paradigm Biocapital Advisors LP |
13F
|
Company |
2%
|
1,437,339
|
$60,785,066 | — | 31 Dec 2024 | |
| T. Rowe Price Investment Management, Inc. |
13F
|
Company |
2%
|
1,415,179
|
$59,848,000 | — | 31 Dec 2024 | |
| Emster Kurt von |
3/4/5
|
Director |
—
mixed-class rows
|
2,987,984
mixed-class rows
|
$53,605,062 | — | 17 May 2021 | |
| First Light Asset Management, LLC |
13F
|
Company |
1.7%
|
1,261,246
|
$53,338,093 | — | 31 Dec 2024 | |
| Abingworth LLP |
3/4/5
|
10%+ Owner |
—
mixed-class rows
|
2,970,156
mixed-class rows
|
$53,284,158 | — | 13 May 2021 | |
| Carlyle Group Inc. |
3/4/5
|
10%+ Owner |
—
class O/S missing
|
2,960,231
|
$53,284,158 | — | 17 Aug 2022 | |
| Woodline Partners LP |
13F
|
Company |
1.7%
|
1,202,466
|
$50,852,287 | — | 31 Dec 2024 | |
| LORD, ABBETT & CO. LLC |
13F
|
Company |
1.6%
|
1,153,670
|
$48,788,000 | — | 31 Dec 2024 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
1.6%
|
1,153,325
|
$48,787,008 | — | 31 Dec 2024 | |
| Integral Health Asset Management, LLC |
13F
|
Company |
1.6%
|
1,150,000
|
$48,633,500 | — | 31 Dec 2024 | |
| FEDERATED HERMES, INC. |
13F
|
Company |
1.5%
|
1,085,986
|
$45,926,348 | — | 31 Dec 2024 | |
| Vestal Point Capital, LP |
13F
|
Company |
1.5%
|
1,075,000
|
$45,461,750 | — | 31 Dec 2024 | |
| Logos Global Management LP |
13F
|
Company |
1.2%
|
875,000
|
$37,003,750 | — | 31 Dec 2024 | |
| Pictet Asset Management Holding SA |
13F
|
Company |
1.2%
|
841,313
|
$35,579,127 | — | 31 Dec 2024 | |
| MARSHALL WACE, LLP |
13F
|
Company |
1.2%
|
837,146
|
$35,402,906 | — | 31 Dec 2024 | |
| JENNISON ASSOCIATES LLC |
13F
|
Company |
1.1%
|
813,861
|
$34,418,182 | — | 31 Dec 2024 | |
| DEUTSCHE BANK AG\ |
13F
|
Company |
1.1%
|
810,376
|
$34,270,802 | — | 31 Dec 2024 | |
| Siren, L.L.C. |
13F
|
Individual |
1%
|
758,465
|
$32,075,485 | — | 31 Dec 2024 | |
| ORBIMED ADVISORS LLC |
13F
|
Company |
1%
|
742,572
|
$31,403,370 | — | 31 Dec 2024 | |
| Longitude Capital Partners IV, LLC |
3/4/5
|
10%+ Owner |
—
class O/S missing
|
1,714,285
|
$30,857,130 | — | 06 Feb 2023 | |
| Longitude Prime Partners, LLC |
3/4/5
|
10%+ Owner |
—
class O/S missing
|
1,714,285
|
$30,857,130 | — | 06 Feb 2023 | |
| VOYA INVESTMENT MANAGEMENT LLC |
13F
|
Company |
0.96%
|
695,091
|
$29,395,398 | — | 31 Dec 2024 | |
| GOLDMAN SACHS GROUP INC |
13F
|
Company |
0.77%
|
554,729
|
$23,459,489 | — | 31 Dec 2024 | |
| Rock Springs Capital Management LP |
13F
|
Company |
0.67%
|
487,863
|
$20,631,726 | — | 31 Dec 2024 | |
| SCHRODER INVESTMENT MANAGEMENT GROUP |
13F
|
Company |
0.67%
|
485,145
|
$20,405,199 | — | 31 Dec 2024 | |
| ADAGE CAPITAL PARTNERS GP, L.L.C. |
13F
|
Company |
0.66%
|
480,000
|
$20,299,200 | — | 31 Dec 2024 | |
| First Turn Management, LLC |
13F
|
Company |
0.64%
|
464,807
|
$19,656,688 | — | 31 Dec 2024 | |
| NORTHERN TRUST CORP |
13F
|
Company |
0.63%
|
455,007
|
$19,242,246 | — | 31 Dec 2024 | |
| Altium Capital Management LLC |
13F
|
Company |
0.6%
|
432,000
|
$18,269,280 | — | 31 Dec 2024 | |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC |
13F
|
Company |
0.6%
|
430,665
|
$18,212,823 | — | 31 Dec 2024 | |
| AMERICAN CENTURY COMPANIES INC |
13F
|
Company |
0.59%
|
428,940
|
$18,139,936 | — | 31 Dec 2024 | |
| Affinity Asset Advisors, LLC |
13F
|
Company |
0.59%
|
425,000
|
$17,973,250 | — | 31 Dec 2024 | |
| BALYASNY ASSET MANAGEMENT L.P. |
13F
|
Company |
0.53%
|
385,425
|
$16,299,623 | — | 31 Dec 2024 | |
| S.c.a. Candriam |
13F
|
Individual |
0.51%
|
365,999
|
$15,478,098 | — | 31 Dec 2024 | |
| MORGAN STANLEY |
13F
|
Company |
0.45%
|
328,515
|
$13,892,900 | — | 31 Dec 2024 | |
| MPM BioImpact LLC |
13F
|
Company |
0.36%
|
257,788
|
$10,901,855 | — | 31 Dec 2024 | |
| AXA S.A. |
13F
|
Company |
0.34%
|
245,879
|
$10,398,223 | — | 31 Dec 2024 |
Institutional Holders of Vera Therapeutics, Inc. - Class A Common Stock, par value $0.001 per share (VERA) as of Q1 2025
As of 31 Mar 2025,
Vera Therapeutics, Inc. - Class A Common Stock, par value $0.001 per share (VERA) was held by
176 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
62,915,975 shares.
The largest 10 holders included
Avoro Capital Advisors LLC, PRICE T ROWE ASSOCIATES INC /MD/, BlackRock, Inc., FMR LLC, VANGUARD GROUP INC, Sofinnova Investments, Inc., COMMODORE CAPITAL LP, Vestal Point Capital, LP, Kynam Capital Management, LP, and Holocene Advisors, LP.
This page lists
176
institutional shareholders reporting positions in this security
for the Q1 2025 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q1 2025 vs Q4 2024 Across Filers
Q4 2024 holders
177
Q1 2025 holders
176
Holder diff
-1
| Investor | Q4 2024 Shares | Q1 2025 Shares | Share Diff | Share Chg % | Q4 2024 Value $ | Q1 2025 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.